CYCCP Key Statistics, Chart & Performance
The current stock price of CYCCP is 5.05 USD. In the past month the price increased by 17.99%. In the past year, price decreased by -96.73%.
CYCCP Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to CYCCP. When comparing the yearly performance of all stocks, CYCCP is a bad performer in the overall market: 99.92% of all stocks are doing better.
CYCCP Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to CYCCP. The financial health of CYCCP is average, but there are quite some concerns on its profitability.
CYCCP Financial Highlights
Over the last trailing twelve months CYCCP reported a non-GAAP Earnings per Share(EPS) of -122.02. The EPS increased by 96.85% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -146.06% | ||
| ROE | -177.03% | ||
| Debt/Equity | 0 |
CYCCP Forecast & Estimates
For the next year, analysts expect an EPS growth of 39.49% and a revenue growth 88.68% for CYCCP
CYCCP Ownership
CYCCP Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.21 | 393.136B | ||
| AMGN | AMGEN INC | 16.27 | 196.357B | ||
| GILD | GILEAD SCIENCES INC | 17.47 | 182.665B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.62 | 117.594B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.77 | 79.341B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 48.11 | 42.669B | ||
| INSM | INSMED INC | N/A | 31.681B | ||
| NTRA | NATERA INC | N/A | 29.21B | ||
| BIIB | BIOGEN INC | 12.57 | 27.736B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.15 | 20.376B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About CYCCP
Company Profile
Cyclacel Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the provision of cell cycle, transcriptional regulation and DNA damage response biology to develop medicines for cancer and other proliferative diseases. The company is headquartered in Berkeley Heights, New Jersey. The firm is focused on developing cancer medicines based on cell cycle, epigenetics and mitosis biology. Its epigenetic/anti-mitotic program is evaluating plogo, a Polo-like kinase 1 (PLK1) inhibitor, in solid tumors and hematological malignancies. PLK1 is a serine/threonine kinase with a central role in cell division, or the mitotic phase of the cell cycle, and is a regulator of the DNA damage checkpoint. The Company’s plogo is a novel, small-molecule, selective and potent PLK1 inhibitor, which has demonstrated potent and selective target inhibition (PLK1 IC50 approximately 3 nM) and efficacy in human tumor xenografts at non-toxic doses. Its translational biology program supports the development of plogo in solid tumor and hematological malignancy indications. PLK1 over-expressing tumors include colorectal, esophageal, gastric, leukemia, lung, lymphoma, ovarian and squamous cell cancers.
Company Info
CYCLACEL PHARMACEUTICALS - CYCC 6 PERP
200 Connell Dr Ste 1500
Berkeley Heights NEW JERSEY 07922 US
CEO: Spiro Rombotis
Employees: 0
Phone: 19085177330
CYCLACEL PHARMACEUTICALS - CYCC 6 PERP / CYCCP FAQ
What does CYCLACEL PHARMACEUTICALS - CYCC 6 PERP do?
Cyclacel Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the provision of cell cycle, transcriptional regulation and DNA damage response biology to develop medicines for cancer and other proliferative diseases. The company is headquartered in Berkeley Heights, New Jersey. The firm is focused on developing cancer medicines based on cell cycle, epigenetics and mitosis biology. Its epigenetic/anti-mitotic program is evaluating plogo, a Polo-like kinase 1 (PLK1) inhibitor, in solid tumors and hematological malignancies. PLK1 is a serine/threonine kinase with a central role in cell division, or the mitotic phase of the cell cycle, and is a regulator of the DNA damage checkpoint. The Company’s plogo is a novel, small-molecule, selective and potent PLK1 inhibitor, which has demonstrated potent and selective target inhibition (PLK1 IC50 approximately 3 nM) and efficacy in human tumor xenografts at non-toxic doses. Its translational biology program supports the development of plogo in solid tumor and hematological malignancy indications. PLK1 over-expressing tumors include colorectal, esophageal, gastric, leukemia, lung, lymphoma, ovarian and squamous cell cancers.
Can you provide the latest stock price for CYCLACEL PHARMACEUTICALS - CYCC 6 PERP?
The current stock price of CYCCP is 5.05 USD. The price decreased by -4.36% in the last trading session.
Does CYCLACEL PHARMACEUTICALS - CYCC 6 PERP pay dividends?
CYCCP does not pay a dividend.
How is the ChartMill rating for CYCLACEL PHARMACEUTICALS - CYCC 6 PERP?
CYCCP has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
On which exchange is CYCCP stock listed?
CYCCP stock is listed on the Nasdaq exchange.
Should I buy CYCCP stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on CYCCP.
Can you provide the market cap for CYCLACEL PHARMACEUTICALS - CYCC 6 PERP?
CYCLACEL PHARMACEUTICALS - CYCC 6 PERP (CYCCP) has a market capitalization of 11.31M USD. This makes CYCCP a Nano Cap stock.